SCD and metabolic syndrome: Elevated cellular activity of SCD1, an enzyme catalyzing the rate-determining step of FA desaturation, which in turn is essential for major synthetic pathways of lipid metabolism, significantly increases the likelihood of developing obesity and related conditions such as the metabolic syndrome, diabetes, insulin resistance and hepatic steatosis17.